| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
When applied to BV2 murine microglia activated by lipopolysaccharide (LPS), gallicin (50 or 100 µM; 7 or 25 hours) reduces the production of proinflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) mRNA and protein expression [1]. In LPS-stimulated BV2 microglia, purpurogallin (100 µM; 75-120 min; BV2 murine microglia) has anti-inflammatory activities by inhibiting the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways[1].
|
|---|---|
| ln Vivo |
Gallicin (100–400 μg/kg; intraperitoneal injection; 48–72 hours; male Sprague-Dawley rats) inhibits the expression of TNF-α and IL-6 mRNA while also decreasing the expression of HMGB1 protein and mRNA. impact of neuroinflammation[2].
|
| Cell Assay |
RT-PCR[1]
Cell Types: BV2 mouse microglia Tested Concentrations: 50 or 100 µM Incubation Duration: 7 or 25 hrs (hours) Experimental Results: Attenuated production of pro-inflammatory cytokines, including interleukin 1β (IL-1β) and tumors Necrosis factor-alpha (TNF-alpha) inhibits its mRNA and protein expression. Western Blot Analysis[1] Cell Types: BV2 Mouse Microglia Tested Concentrations: 100 µM Incubation Duration: 75 min, 90 min, 120 min Experimental Results: Inhibition of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signal path. |
| Animal Protocol |
Animal/Disease Models: 54 male subarachnoid hemorrhage (SAH) rats (250-350 g) [2]
Doses: 100 μg/kg, 200 μg/kg, 400 μg/kg Route of Administration: intraperitoneal (ip) injection; 48 or Results at 72 hrs (hrs (hours)): dose-dependent reduction of HMGB1 protein expression. High doses diminished TNF-α and HMGB1 mRNA levels. |
| References |
|
| Molecular Formula |
C11H8O5
|
|---|---|
| Molecular Weight |
220.17822
|
| Exact Mass |
220.037
|
| CAS # |
569-77-7
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.74g/cm3
|
| Boiling Point |
357.9ºC at 760mmHg
|
| Melting Point |
275ºC (dec.)(lit.)
|
| Flash Point |
184.5ºC
|
| Index of Refraction |
1.79
|
| LogP |
1.022
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~454.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5417 mL | 22.7087 mL | 45.4174 mL | |
| 5 mM | 0.9083 mL | 4.5417 mL | 9.0835 mL | |
| 10 mM | 0.4542 mL | 2.2709 mL | 4.5417 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
